Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Open Label Multicenter Phase II Study of First Line Therapy With Sorafenib in Association With IL-2 vs Sorafenib Alone in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma

NCT00609401 is registered in ClinicalTrials.gov with Italian Trial in Medical Oncology as lead sponsor.

NCT NCT00609401
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00609401 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Open Label Multicenter Phase II Study of First Line Therapy With Sorafenib in Association With IL-2 vs Sorafenib Alone in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma
Lead sponsor
Italian Trial in Medical Oncology
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2006
Completion date
May 31, 2008
Enrollment
90 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic disease, renal cell carcinoma